Article
Hematology
Robert Zeiser, Gerard Socie, Mark A. Schroeder, Sunil A. Bhyankar, Carlos Pinho Vaz, Mi Kwon, Johannes Clausen, Leonid Volodin, Sebastian Glebel, Manuel Jurado Chacon, Gabrielle Meyers, Maidsa Ghosh, Dries Deeren, Jaime Sanz, Rodica Morariu-Zamfir, Michael Arbushites, Mani Lakshminarayanan, April M. Barbour, Yi-Bin Chen
Summary: This study aimed to evaluate the effectiveness of Janus kinase 1 inhibitor itacitinib in combination with corticosteroids for the treatment of acute graft-versus-host disease (GVHD). The results did not show a significant improvement in overall response rate at day 28 compared to placebo. Further research is needed to determine the utility of selective JAK1 inhibition for treating acute GVHD.
LANCET HAEMATOLOGY
(2022)
Article
Medicine, General & Internal
Brad H. Rovin, Y. K. Onno Teng, Ellen M. Ginzler, Cristina Arriens, Dawn J. Caster, Juanita Romero-Diaz, Keisha Gibson, Joshua Kaplan, Laura Lisk, Sandra Navarra, Samir V. Parikh, Simrat Randhawa, Neil Solomons, Robert B. Huizinga
Summary: This study evaluated the efficacy and safety of voclosporin for the treatment of lupus nephritis, showing a superior complete renal response rate with voclosporin in combination with MMF and low-dose steroids compared to MMF and low-dose steroids alone. The safety profile was comparable between the two groups. This finding represents an important advancement in the treatment of patients with active lupus nephritis.
Article
Oncology
Dean A. Fennell, Sean Ewings, Christian Ottensmeier, Raffaele Califano, Gerard G. Hanna, Kayleigh Hill, Sarah Danson, Nicola Steele, Mavis Nye, Lucy Johnson, Joanne Lord, Calley Middleton, Peter Szlosarek, Sam Chan, Aarti Gaba, Liz Darlison, Peter Wells-Jordan, Cathy Richards, Charlotte Poile, Jason F. Lester, Gareth Griffiths
Summary: The study evaluated the efficacy and safety of nivolumab in patients with pleural or peritoneal malignant mesothelioma who had progressed following platinum-based chemotherapy. Nivolumab showed improved progression-free survival and overall survival compared to placebo in these patients, with manageable treatment-related adverse events. The results suggest that nivolumab might be a beneficial treatment for patients with malignant mesothelioma who have progressed on first-line therapy.
Article
Medicine, General & Internal
Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, Elena Elez, Takayuki Yoshino, Alberto Sobrero, James Yao, Pilar Garcia-Alfonso, Judit Kocsis, Antonio Cubillo Gracian, Andrea Sartore-Bianchi, Taroh Satoh, Violaine Randrian, Jiri Tomasek, Geoff Chong, Andrew Scott Paulson, Toshiki Masuishi, Jeremy Jones, Tibor Csoszi, Chiara Cremolini, Francois Ghiringhelli, Ardaman Shergill, Howard S. Hochster, John Krauss, Ali Bassam, Michel Ducreux, Anneli Elme, Laurence Faugeras, Stefan Kasper, Eric Van Cutsem, Dirk Arnold, Shivani Nanda, Zhao Yang, William R. Schelman, Marek Kania, Josep Tabernero, Cathy Eng
Summary: This study evaluated the efficacy and safety of fruquintinib, a highly selective and potent oral inhibitor of VEGFRs 1, 2, and 3, in patients with advanced, chemotherapy-refractory colorectal cancer. The results showed that fruquintinib significantly prolonged overall survival compared to placebo in patients with refractory metastatic colorectal cancer, with clinical significance. Therefore, fruquintinib could become a global treatment option for patients with refractory metastatic colorectal cancer.
Article
Medicine, General & Internal
Elsa Tavernier, Francois Barbier, Ferhat Meziani, Jean-Pierre Quenot, Jean-Etienne Herbrecht, Mickael Landais, Damien Roux, Philippe Seguin, David Schnell, Anne Veinstein, Benoit Veber, Sigismond Lasocki, Qin Lu, Gaetan Beduneau, Martine Ferrandiere, Claire Dahyot-Fizelier, Gaetan Plantefeve, Mai-Anh Nay, Hamid Merdji, Pascal Andreu, Laurent Vecellio, Gregoire Muller, Maria Cabrera, Deborah Le Pennec, Renaud Respaud, Philippe Lanotte, Nicolas Gregoire, Marie Leclerc, Julie Helms, Thierry Boulain, Jean-Claude Lacherade, Stephan Ehrmann
Summary: Pre-emptive inhaled antibiotics may reduce ventilator-associated pneumonia among critically ill patients, with potential benefits for those undergoing invasive mechanical ventilation for over 3 days. This randomized controlled trial aims to evaluate the effectiveness of a 3-day course of inhaled antibiotics in preventing ventilator-associated pneumonia.
Article
Medicine, General & Internal
Thomas Schmitz, Muriel Doret-Dion, Loic Sentilhes, Olivier Parant, Olivier Claris, Laurent Renesme, Julie Abbal, Aude Girault, Heloise Torchin, Marie Houllier, Nolwenn Le Sache, Alexandre J. Vivanti, Daniele De Luca, Norbert Winer, Cyril Flamant, Claire Thuillier, Pascal Boileau, Julie Blanc, Veronique Brevaut, Pierre-Emmanuel Bouet, Geraldine Gascoin, Gael Beucher, Valerie Datin-Dorriere, Stephane Bounan, Pascal Bolot, Christophe Poncelet, Corinne Alberti, Moreno Ursino, Camille Aupiais, Olivier Baud
Summary: Comparison between a full dose and a half dose of antenatal betamethasone for preterm delivery showed that the half dose was not non-inferior to the full dose in terms of preventing respiratory distress syndrome. Therefore, reducing the dose of antenatal betamethasone is not recommended.
Article
Gastroenterology & Hepatology
Katsuyoshi Matsuoka, Mamoru Watanabe, Toshihide Ohmori, Koichi Nakajima, Tetsuya Ishida, Yoh Ishiguro, Kazunari Kanke, Kiyonori Kobayashi, Fumihito Hirai, Kenji Watanabe, Hidehiro Mizusawa, Shuji Kishida, Yoshiharu Miura, Akira Ohta, Toshifumi Kajioka, Toshifumi Hibi
Summary: This study evaluated the efficacy and safety of oral small-molecule drug AJM300 in patients with moderately active ulcerative colitis, showing that AJM300 could be a novel induction therapy for this condition.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Stephen A. Harrison, Juan P. Frias, Guy Neff, Gary A. Abrams, K. Jean Lucas, William Sanchez, Sudhanshu Gogia, Muhammed Y. Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Doreen Chan, Erica Fong, Brittany de Temple, Reshma Shringarpure, Erik J. Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale
Summary: The study evaluated the efficacy and safety of the bivalent Fc-FGF21 analogue Efruxifermin in patients with NASH and moderate or severe fibrosis. The results showed that Efruxifermin improved liver fibrosis and resolved NASH over 24 weeks with acceptable tolerability, supporting further assessment in phase 3 trials.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Oncology
Qing Zhou, Ming Chen, Ou Jiang, Yi Pan, Desheng Hu, Qin Lin, Gang Wu, Jiuwei Cui, Jianhua Chang, Yufeng Cheng, Cheng Huang, Anwen Liu, Nong Yang, Youling Gong, Chuan Zhu, Zhiyong Ma, Jian Fang, Gongyan Chen, Jun Zhao, Anhui Shi, Yingcheng Lin, Guanghui Li, Yunpeng Liu, Dong Wang, Rong Wu, Xinhua Xu, Jianhua Shi, Zhihua Liu, Na Cui, Jingru Wang, Qiang Wang, Ran Zhang, Jason Yang, Yi-Long Wu
Summary: The efficacy and safety of sugemalimab, an anti-PD-L1 antibody, were assessed in patients with unresectable stage III non-small-cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy. The results showed that sugemalimab significantly prolonged progression-free survival in these patients.
Article
Rheumatology
Pascal Richette, Augustin Latourte, Jeremie Sellam, Daniel Wendling, Muriel Piperno, Philippe Goupille, Yves-Marie Pers, Florent Eymard, Sebastien Ottaviani, Paul Ornetti, Rene-Marc Flipo, Bruno Fautrel, Olivier Peyr, Jean Pierre Bertola, Eric Vicaut, Xavier Chevalier
Summary: The study found that tocilizumab was not more effective than placebo in relieving pain in patients with hand osteoarthritis. Apart from the primary endpoint, there were no significant differences in secondary outcomes between the tocilizumab group and the placebo group.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Oncology
Sun Young Rha, Do-Youn Oh, Patricio Yanez, Yuxian Bai, Min-Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai-Keen Shiu, Manuel Gonzalez Fernandez, Jin Li, Maeve A. Lowery, Timucin Cil, Felipe Melo Cruz, Shukui Qin, Suxia Luo, Hongming Pan, Zev A. Wainberg, Lina Yin, Sonal Bordia, Pooja Bhagia, Lucjan S. Wyrwicz
Summary: This study compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy for locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma. The results showed that participants in the pembrolizumab plus chemotherapy group had a significant and clinically meaningful improvement in overall survival with manageable toxicity.
Article
Clinical Neurology
Mark Obermann, Steffen Naegel, Claudia Ose, Niluefer Sonuc, Andre Scherag, Peter Storch, Charly Gaul, Andreas Boeger, Torsten Kraya, Jan-Peter Jansen, Andreas Straube, Tobias Freilinger, Holger Kaube, Tim P. Juergens, Hans-Christoph Diener, Zaza Katsarava, Christoph Kleinschnitz, Dagny Holle
Summary: This study aimed to evaluate the safety and efficacy of prednisone in the treatment of episodic cluster headaches. The results showed that prednisone was an effective short-term preventive therapy, reducing the number of headache attacks and demonstrating good safety profile.
Article
Medicine, General & Internal
Sumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, Viraj A. Master, Frede Donskov, Cristina Suarez, Laurence Albiges, Brian Rini, Yoshihiko Tomita, Ariel Galapo Kann, Giuseppe Procopio, Francesco Massari, Matthew Zibelman, Igor Antonyan, Mahrukh Huseni, Debasmita Basu, Bo Ci, William Leung, Omara Khan, Sarita Dubey, Axel Bex
Summary: The objective of this study was to determine if adjuvant atezolizumab delayed recurrence in renal cell carcinoma patients with an increased risk of recurrence. The study found that adjuvant atezolizumab did not improve clinical outcomes in patients with renal cell carcinoma.
Article
Medicine, General & Internal
Andrew W. Horne, Stephen Tong, Catherine A. Moakes, Lee J. Middleton, W. Colin Duncan, Ben W. Mol, Lucy H. R. Whitaker, Davor Jurkovic, Arri Coomarasamy, Natalie Nunes, Tom Holland, Fiona Clarke, Ann M. Doust, Jane P. Daniels
Summary: This study evaluated whether oral gefitinib in combination with methotrexate is more effective than methotrexate alone in the treatment of tubal ectopic pregnancy. The results showed that oral gefitinib does not offer clinical benefit over methotrexate and increases minor adverse reactions.
Article
Rheumatology
Renaud Felten, Valerie Devauchelle-Pensec, Raphaele Seror, Pierre Duffau, David Saadoun, Eric Hachulla, Hatron Pierre Yves, Carine Salliot, Aleth Perdriger, Jacques Morel, Arsene Mekinian, Olivier Vittecoq, Jean-Marie Berthelot, Emanuelle Dernis, Veronique Le Guern, Philippe Dieude, Claire Larroche, Christophe Richez, Thierry Martin, Charles Zarnitsky, Gilles Blaison, Pierre Kieffer, Francois Maurier, Azeddine Dellal, Stephanie Rist, Emmanuel Andres, Anne Contis, Emmanuel Chatelus, Christelle Sordet, Jean Sibilia, Cecile Arnold, Mira Y. Tawk, Ouafaa Aberkane, Lise Holterbach, Patrice Cacoub, Alain Saraux, Xavier Mariette, Nicolas Meyer, Jacques-Eric Gottenberg
Summary: This study aimed to demonstrate the efficacy of targeting interleukin 6 receptor in patients with primary Sjogren's syndrome-related systemic complications. However, the results showed that over 24 weeks of treatment, tocilizumab did not improve systemic involvement and symptoms in patients with primary Sjogren's syndrome.
ANNALS OF THE RHEUMATIC DISEASES
(2021)